Eli Lilly Beats Earnings, Stock Soars 2% Despite GLP-1 Miss
Eli Lilly (LLY) reported its fourth quarter and full-year earnings on Thursday, beating Wall Street estimates. The company’s stock surged about 2%. However, the results missed expectations for GLP-1 sales. The pharmaceutical giant has had mixed results recently. Its FDA-approved GLP-1 tirzepatide drugs were removed from the drug shortage list, but the company revised its … Read more